EAM
CBIO

Exome Asset Management’s Crescent Biopharma CBIO Stock Holding History

Exome Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Sell
127,769
-25,422
-17% -$496K 1.42% 26
2026
Q1 		$2.81M Buy
+153,191
New +$1.76M 1.46% 31

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Exome Asset Management's CBIO Position: Q2 2026 in Review

Exome Asset Management reduced its Crescent Biopharma (CBIO) stake by 17% in Q2 2026, selling an estimated $496K and leaving 127,769 shares worth $2.3M. The position accounts for 1.42% of the portfolio, ranked #26.

Exome Asset Management first reported a position in CBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.81M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Exome Asset Management held 127,769 shares of Crescent Biopharma worth $2.3M as of Q2 2026.
  • Exome Asset Management sold 25,422 Crescent Biopharma shares in Q2 2026, an estimated $496K.
  • Crescent Biopharma made up 1.42% of Exome Asset Management's portfolio in Q2 2026, its #26 holding.
  • Exome Asset Management first reported a position in Crescent Biopharma in Q1 2026 and has held it in 2 quarters since.
  • Exome Asset Management's Crescent Biopharma position peaked at $2.81M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.